Show results for
Refine by
Artery Pressures Articles & Analysis
15 news found
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary ...
Invasive devices, such as pulmonary artery pressure sensors, allow for remote measures of clinical congestion and titration of heart failure therapy, but their widespread use is limited by the need for an invasive procedure, a relatively narrow indication for use in patients, and high cost of implantation. ...
There were no observed changes among subject’s intra-day maximal oxygen consumption tests or in subject’s partial pressure of arterial blood oxygen. TSC was safe and well-tolerated at all doses tested in the study with no serious adverse events reported. ...
ByCervoMed
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in New York Heart Association (NYHA) class III heart failure ...
The study titled, “Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure,” sought to test the relationship (or lack thereof) between a commercially available implantable pulmonary artery pressure (PAP) monitor, estimates of cardiac blood volume, and actual ...
Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor1, shifting the design from a randomized control study to a single-arm study. ...
However, we observed that Aeson® has been able to directly intraoperatively stabilize the hemodynamic situation of the patient and has also been able to cope with the high pulmonary arterial pressures. Overall, we have been impressed by the promising performance of the device and we are looking forward to include it in our portfolio to save many lives in the ...
ByCarmat
“I am excited to join Endotronix as the company prepares for commercial launch and rapid growth in this duopoly interventional heart failure segment, pulmonary artery (PA) pressure-guided HF management. And I look forward to leveraging my diverse experiences to accelerate the company along its mission to transform the standard of care for chronic heart ...
V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has closed a Series C extension of up to $98M. ...
The trial is a pre-market investigational device exempt (IDE) study evaluating the safety and efficacy of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor) for the treatment of HF. ...
-based Endotronix, Inc. and Tyndall will explore the application of novel electronics technologies to wireless, implantable sensors for chronic disease management, such as the Cordella Pulmonary Artery Pressure Sensor System (Cordella Sensor). “Together our Cordella Sensor and Cordella System provide a robust platform for data-guided chronic disease ...
The funds will be used to support the landmark PROACTIVE-HF IDE clinical trial of the Cordella Pulmonary Artery Sensor System (Cordella Sensor) and commercialization of the Cordella Heart Failure System (Cordella System). ...
The 60-patient study will evaluate safety and efficacy of the Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in support of its CE Mark submission. ...
The platform consists of a comprehensive remote patient management system coupled with a seamlessly integrated, next generation implantable pulmonary artery (PA) pressure sensor to streamline heart failure care management, reduce heart-failure-related hospitalizations, and support reimbursement for care delivery activities. ...